dCK inhibitors have demonstrated the potential to mitigate the manifestations of multiple sclerosis in mouse models, and dCK-specific PET probe accumulation has been proposed as a potential non-invasive biomarker for these inhibitors in patients (37, 123, 184, 185). The gene discussed is DCK; the disease is multiple sclerosis.